ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Haisco Pharmaceutical Group, Bayer and AstraZeneca side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Haisco Pharmaceutical Group×Bayer×AstraZeneca×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Haisco Pharmaceutical GroupBayerAstraZeneca
studies on the registry1591,6944,197
open to participants now5360298
phase 3 studies under way1111200
reach primary completion within a year2135168
programswith a study of their own in two years2721119+5 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHaisco Pharmaceutical GroupBayerAstraZeneca
Phase 1

Haisco Pharmaceutical Group: 14 of its 27 programs at phase 1

  1. HSK41959phase 1
  2. HSK46256phase 1
  3. HSK46575phase 1
  4. HSK47977phase 1
  5. HSK55879phase 1

and 9 more — sign in to see them all

52%
19%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%
Phase 2

Haisco Pharmaceutical Group: 5 of its 27 programs at phase 2

  1. HSK42360phase 2
  2. HSK47388phase 2
  3. HSK55718phase 2
  4. Cetuximabphase 2
  5. HSK50042phase 2
19%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
Phase 3

Haisco Pharmaceutical Group: 7 of its 27 programs at phase 3

  1. florensocatibphase 3
  2. HSK44459phase 3
  3. HSK39004phase 3
  4. HSK39297phase 3
  5. anrikefonphase 3

and 2 more — sign in to see them all

26%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
Approved, new studies

Haisco Pharmaceutical Group: 1 of its 27 programs at approved, new studies

  1. ciprofolapproved, new study
4%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Haisco Pharmaceutical Group9 readouts · 1 phase 3

Haisco Pharmaceutical Group, Nov ’26: 2 programs whose next study reaches primary completion

  1. florensocatibphase 3 · Nov 0 · NCT07915024
  2. HSK55718phase 2 · Nov 0 · NCT07551739

Haisco Pharmaceutical Group, Dec ’26: 3 programs whose next study reaches primary completion

  1. HSK46575phase 1 · Dec 0 · NCT07007910
  2. HSK39297phase 3 · Dec 5 · NCT07616700
  3. HSK47388phase 2 · Dec 20 · NCT07158268
··

Haisco Pharmaceutical Group, Mar ’27: 1 program whose next study reaches primary completion

  1. HSK44459phase 3 · Mar 0 · NCT07623486
··

Haisco Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HSK39004phase 3 · Jun 11 · NCT07658339
  2. cofrogliptinno phase · Jun 30 · NCT07122102
··

Haisco Pharmaceutical Group, Sep ’27: 1 program whose next study reaches primary completion

  1. HSK60002 tabletsphase 1 · Sep 0 · NCT07920809
·
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Haisco Pharmaceutical Group

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Where they overlap

Conditions where at least two of them have programs: 34 in all. A program counts in each condition its studies name most.

ConditionHaisco Pharmaceutical GroupBayerAstraZeneca
Carcinoma, Non-Small-Cell Lungall three · compare here

Haisco Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2all three · compare here

Haisco Pharmaceutical Group in Diabetes Mellitus, Type 2: 4 programs

  1. HSK7653phase 3
  2. Carbon-14phase 1
  3. Ranolazinephase 1
  4. cofrogliptinno phase

Their studies: Haisco Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Bayer in Diabetes Mellitus, Type 2: 2 programs

  1. finerenoneapproved, new study
  2. Levonorgestrelapproved, new study

Their studies: Bayer’s studies of Diabetes Mellitus, Type 2 in search

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Renal Insufficiency, Chronicall three · compare here

Haisco Pharmaceutical Group in Renal Insufficiency, Chronic: 1 program

  1. ciprofolapproved, new study

Their studies: Haisco Pharmaceutical Group’s studies of Renal Insufficiency, Chronic in search

Bayer in Renal Insufficiency, Chronic: 2 programs

  1. nurandociguatphase 2
  2. finerenoneapproved, new study

Their studies: Bayer’s studies of Renal Insufficiency, Chronic in search

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

Neoplasmsall three · compare here

Haisco Pharmaceutical Group in Neoplasms: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Neoplasms in search

Bayer in Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Cardiovascular Diseasesall three · compare here

Haisco Pharmaceutical Group in Cardiovascular Diseases: 1 program

  1. Ranolazinephase 1

Their studies: Haisco Pharmaceutical Group’s studies of Cardiovascular Diseases in search

Bayer in Cardiovascular Diseases: 1 program

  1. Aspirinapproved, new study

Their studies: Bayer’s studies of Cardiovascular Diseases in search

AstraZeneca in Cardiovascular Diseases: 2 programs

  1. laroprovstatphase 3
  2. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Cardiovascular Diseases in search

Colorectal Neoplasmsall three · compare here

Haisco Pharmaceutical Group in Colorectal Neoplasms: 2 programs

  1. HSK42360phase 2
  2. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Bayer in Colorectal Neoplasms: 1 program

  1. WRN Inhibitor RO7589831phase 2

Their studies: Bayer’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Coronary Artery Diseaseall three · compare here

Haisco Pharmaceutical Group in Coronary Artery Disease: 1 program

  1. Ranolazinephase 1

Their studies: Haisco Pharmaceutical Group’s studies of Coronary Artery Disease in search

Bayer in Coronary Artery Disease: 2 programs

  1. nurandociguatphase 2
  2. Aspirinapproved, new study

Their studies: Bayer’s studies of Coronary Artery Disease in search

AstraZeneca in Coronary Artery Disease: 1 program

  1. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Coronary Artery Disease in search

Prostatic Neoplasms2 of 3 · compare here–

Bayer in Prostatic Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Prostatic Neoplasms in search

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Asthma2 of 3 · compare here

Haisco Pharmaceutical Group in Asthma: 1 program

  1. florensocatibphase 3

Their studies: Haisco Pharmaceutical Group’s studies of Asthma in search

–

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Renal Insufficiency2 of 3 · compare here

Haisco Pharmaceutical Group in Renal Insufficiency: 2 programs

  1. anrikefonphase 3
  2. HSK7653phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Renal Insufficiency in search

–

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

Haisco Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 1 program

  1. HSK39004phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

–

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Carcinoma, Hepatocellular2 of 3 · compare here–

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Heart Failure2 of 3 · compare here–

Bayer in Heart Failure: 1 program

  1. finerenoneapproved, new study

Their studies: Bayer’s studies of Heart Failure in search

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

Hemoglobinuria, Paroxysmal2 of 3 · compare here

Haisco Pharmaceutical Group in Hemoglobinuria, Paroxysmal: 2 programs

  1. HSK39297phase 3
  2. Carbon-14phase 1

Their studies: Haisco Pharmaceutical Group’s studies of Hemoglobinuria, Paroxysmal in search

–

AstraZeneca in Hemoglobinuria, Paroxysmal: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Hemoglobinuria, Paroxysmal in search

Neoplasm Metastasis2 of 3 · compare here–

Bayer in Neoplasm Metastasis: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasm Metastasis in search

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Parkinson Disease2 of 3 · compare here

Haisco Pharmaceutical Group in Parkinson Disease: 2 programs

  1. Carbon-14phase 1
  2. Pramipexolephase 1

Their studies: Haisco Pharmaceutical Group’s studies of Parkinson Disease in search

Bayer in Parkinson Disease: 2 programs

  1. bemdaneprocelphase 3
  2. AB-1005phase 2

Their studies: Bayer’s studies of Parkinson Disease in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

Haisco Pharmaceutical Group in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Squamous Cell Carcinoma of Head and Neck in search

–

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Amyloidosis2 of 3 · compare here–

Bayer in Amyloidosis: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloidosis in search

AstraZeneca in Amyloidosis: 2 programs

  1. cliramitugphase 3
  2. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis in search

Dermatitis, Atopic2 of 3 · compare here

Haisco Pharmaceutical Group in Dermatitis, Atopic: 2 programs

  1. HSK44459phase 3
  2. HSK60002 tabletsphase 1

Their studies: Haisco Pharmaceutical Group’s studies of Dermatitis, Atopic in search

–

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Hepatic Insufficiency2 of 3 · compare here–

Bayer in Hepatic Insufficiency: 1 program

  1. sevabertinibphase 3

Their studies: Bayer’s studies of Hepatic Insufficiency in search

AstraZeneca in Hepatic Insufficiency: 2 programs

  1. atirmociclibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Hepatic Insufficiency in search

Hypercholesterolemia2 of 3 · compare here

Haisco Pharmaceutical Group in Hypercholesterolemia: 1 program

  1. HSK31679phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Hypercholesterolemia in search

–

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Idiopathic Pulmonary Fibrosis2 of 3 · compare here

Haisco Pharmaceutical Group in Idiopathic Pulmonary Fibrosis: 2 programs

  1. HSK44459phase 3
  2. HSK50042phase 2

Their studies: Haisco Pharmaceutical Group’s studies of Idiopathic Pulmonary Fibrosis in search

–

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Sepsis2 of 3 · compare here–

Bayer in Sepsis: 1 program

  1. BAY 3389934phase 1

Their studies: Bayer’s studies of Sepsis in search

AstraZeneca in Sepsis: 2 programs

  1. Berzanoflastphase 2
  2. AZD7760phase 2

Their studies: AstraZeneca’s studies of Sepsis in search

Amyloid Neuropathies, Familial2 of 3 · compare here–

Bayer in Amyloid Neuropathies, Familial: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloid Neuropathies, Familial in search

AstraZeneca in Amyloid Neuropathies, Familial: 1 program

  1. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloid Neuropathies, Familial in search

Amyloidosis, Hereditary, Transthyretin-Related2 of 3 · compare here–

Bayer in Amyloidosis, Hereditary, Transthyretin-Related: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloidosis, Hereditary, Transthyretin-Related in search

AstraZeneca in Amyloidosis, Hereditary, Transthyretin-Related: 1 program

  1. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis, Hereditary, Transthyretin-Related in search

Atrial Fibrillation2 of 3 · compare here

Haisco Pharmaceutical Group in Atrial Fibrillation: 1 program

  1. Ranolazinephase 1

Their studies: Haisco Pharmaceutical Group’s studies of Atrial Fibrillation in search

Bayer in Atrial Fibrillation: 1 program

  1. BAY 3670549phase 2

Their studies: Bayer’s studies of Atrial Fibrillation in search

–
Bronchiectasis2 of 3 · compare here

Haisco Pharmaceutical Group in Bronchiectasis: 1 program

  1. florensocatibphase 3

Their studies: Haisco Pharmaceutical Group’s studies of Bronchiectasis in search

–

AstraZeneca in Bronchiectasis: 1 program

  1. AZD0292phase 2

Their studies: AstraZeneca’s studies of Bronchiectasis in search

Colitis, Ulcerative2 of 3 · compare here

Haisco Pharmaceutical Group in Colitis, Ulcerative: 1 program

  1. HSK47388phase 2

Their studies: Haisco Pharmaceutical Group’s studies of Colitis, Ulcerative in search

–

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

Diabetic Nephropathies2 of 3 · compare here–

Bayer in Diabetic Nephropathies: 1 program

  1. finerenoneapproved, new study

Their studies: Bayer’s studies of Diabetic Nephropathies in search

AstraZeneca in Diabetic Nephropathies: 1 program

  1. tozorakimabphase 3

Their studies: AstraZeneca’s studies of Diabetic Nephropathies in search

Glomerulonephritis, IGA2 of 3 · compare here

Haisco Pharmaceutical Group in Glomerulonephritis, IGA: 1 program

  1. HSK39297phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Glomerulonephritis, IGA in search

–

AstraZeneca in Glomerulonephritis, IGA: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Glomerulonephritis, IGA in search

Head and Neck Neoplasms2 of 3 · compare here

Haisco Pharmaceutical Group in Head and Neck Neoplasms: 1 program

  1. Cetuximabphase 2

Their studies: Haisco Pharmaceutical Group’s studies of Head and Neck Neoplasms in search

–

AstraZeneca in Head and Neck Neoplasms: 1 program

  1. monalizumabphase 3

Their studies: AstraZeneca’s studies of Head and Neck Neoplasms in search

Lupus Nephritis2 of 3 · compare here

Haisco Pharmaceutical Group in Lupus Nephritis: 1 program

  1. HSK39297phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Lupus Nephritis in search

–

AstraZeneca in Lupus Nephritis: 1 program

  1. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Lupus Nephritis in search

Non-alcoholic Fatty Liver Disease2 of 3 · compare here

Haisco Pharmaceutical Group in Non-alcoholic Fatty Liver Disease: 1 program

  1. HSK31679phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Non-alcoholic Fatty Liver Disease in search

–

AstraZeneca in Non-alcoholic Fatty Liver Disease: 1 program

  1. AZD9550phase 2

Their studies: AstraZeneca’s studies of Non-alcoholic Fatty Liver Disease in search

Thrombosis2 of 3 · compare here–

Bayer in Thrombosis: 1 program

  1. Aspirinapproved, new study

Their studies: Bayer’s studies of Thrombosis in search

AstraZeneca in Thrombosis: 1 program

  1. andexanet alfaapproved, new study

Their studies: AstraZeneca’s studies of Thrombosis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Haisco Pharmaceutical Group 7 of 27 · Bayer 13 of 21 · AstraZeneca 68 of 119 programs (49 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).